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Abstract: Vaccine development is an expensive and time-consuming process that heavily relies
on animal models. Yet, vaccine candidates that have previously succeeded in animal experiments
often fail in clinical trials questioning the predictive value of animal models. Alternative assay
systems that can add to the screening and evaluation of functional characteristics of vaccines in a
human context before embarking on costly clinical trials are therefore urgently needed. In this study,
we have established an in vitro system consisting of long-term cultures of unfractionated peripheral
blood mononuclear cells (PBMCs) from healthy volunteers to assess (recall) T cell responses to
vaccine candidates. We observed that different types of influenza vaccines (whole inactivated virus
(WIV), split, and peptide vaccines) were all able to stimulate CD4 and CD8 T cell responses but to
different extents in line with their reported in vivo properties. In-depth analyses of different T cell
subsets revealed that the tested vaccines evoked mainly recall responses as indicated by the fact that
the vast majority of the responding T cells had a memory phenotype. Furthermore, we observed
vaccine-induced activation of T follicular helper cells, which are associated with the induction of
humoral immune responses. Our results demonstrate the suitability of the established PBMC-based
system for the in vitro evaluation of memory T cell responses to vaccines and the comparison of
vaccine candidates in a human immune cell context. As such, it can help to bridge the gap between
animal experiments and clinical trials and assist in the selection of promising vaccine candidates,
at least for recall antigens.
Keywords: vaccines; in vitro; T cells; T follicular helper cells; influenza; WIV; split; peptides
1. Introduction
Vaccination is the primary measure for the control of infectious diseases and, in light of increasing
resistance of microorganisms to antimicrobial treatment, might even gain more importance in the future.
Yet, vaccine development is an expensive and time-consuming process with only a few successful
outcomes. During vaccine development, monitoring vaccine immunogenicity represents a key step
that, to date, essentially relies on animal testing. However, the predictive value of small animal models
for the situation in humans is often poor due to intrinsic differences between the immune systems
and very different immune biographies [1]. As a consequence, numerous vaccine candidates that
succeeded in animal experiments subsequently performed poorly in clinical trials [2,3]. Frequent
failure of vaccines during expensive clinical trials highlights the need for innovative experimental
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systems that can provide information about functional characteristics of vaccines in a human context,
thus bridging the gap between the preclinical and clinical evaluation of vaccine candidates.
Ideally, such systems would include different modules, allowing the assessment of vaccine
effects on responses of antigen-presenting cells (APC) as well as T and B cells. We and others have
previously established an APC module for determining the capacity of vaccines to induce innate
immune responses [4,5]. Using this system, we demonstrated that primary human monocyte-derived
dendritic cells (DCs) respond to different types of influenza vaccines in qualitatively and quantitatively
characteristic ways, in line with the known in vivo properties of these vaccine types [4]. In the current
paper, we focus on the T cell module, by evaluating an experimental system, which allows a detailed
characterization of vaccine-evoked responses of human CD4+ and CD8+ T cells.
To this end, we set up long-term cultures of unfractionated human peripheral blood mononuclear
cells (PBMCs). As a proof of principle, we evaluated and characterized, in these cultures, (memory) T
cell-mediated responses induced by two different well-characterized influenza vaccine formulations,
H5N1-derived whole inactivated virus (WIV), and split virus, and further validated the model for a
peptide-based influenza vaccine formulation. Activation, proliferation, increase of cytotoxic potential,
and IFNγ responses were detected when the PBMCs were stimulated with WIV, split virus vaccine,
or influenza peptides. Phenotyping of the CD4+ and CD8+ T cells revealed that the vaccines mainly
evoked responses of effector memory and central memory T cell subsets, as expected. Interestingly,
we could also identify vaccine-induced follicular T helper cell (TFH) responses. These data underscore
the utility of the developed PBMC-based system to potentially bridge the gap between animal
experiments and clinical trials and to assist in the selection of the most promising vaccine candidates
for clinical evaluation, at least for recall antigens.
2. Materials and Methods
2.1. Virus and Vaccines
The H5N1 virus (NIBRG-14, a 2:6 recombinant of A/Vietnam/1194/2004 (H5N1) and A/PR/8/34
(H1N1) virus produced by reverse genetics technology) was obtained from the National Institute for
Biological Standards and Control, Potters Bar, United Kingdom. WIV and split vaccines were produced
from this virus, as described before [4]. Briefly, H5N1 was propagated in embryonated chicken eggs
and inactivated with 0.1% β-propiolactone for 24 h at 19–21◦C, followed by dialysis and filtration
(0.45 µm) to obtain WIV. A fraction of the WIV vaccine was then used to produce a split virus vaccine,
as previously described [6]. In short, Triton X-100 was added to WIV in the presence of Tween 80,
and the suspension was stirred for 1 h at 20 ◦C. Detergents were removed by overnight rotation of the
vaccine together with Biobeads (Bio-Rad, Hercules, CA, USA) at 4◦C. Vaccines were then characterized
by SDS-PAGE, followed by silver staining. Protein content was determined by Lowry assay.
2.2. Peptides
From a previous publication [7], we selected four different peptides representing 2 CD4 and 2 CD8
influenza epitopes. The peptides (lyophilized acetate salt; >98.0% purity, Caslo ApS, Lyngby, Denmark)
were derived from the NP and the M protein of influenza A H3N2 virus and were highly conserved
across a range of influenza virus strains. The peptides were selected such that they could be presented
by several MHC haplotypes (Appendix A Table A1). A commercial peptide mixture consisting of 23
HLA class I-restricted T cell epitopes from cytomegalovirus, Epstein-Barr virus, and influenza virus
(CEF pool standard; JPT, Berlin, Germany) was used as the positive control.
2.3. Human Primary Cells
Human PBMCs were isolated from buffy coats from healthy volunteers (with unknown vaccination
status) obtained from the Dutch blood bank (Sanquin, Nijmegen, The Netherlands). PBMCs were
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isolated by density gradient using Ficoll Paque (GE Healthcare, Uppsala, Sweden), as previously
described [4]. PBMCs were stored in liquid nitrogen until needed.
2.4. In Vitro Stimulation Using Influenza Vaccines and Peptides
PBMCs were thawed in a water bath at 37◦C, as previously described [4]. Cells were seeded at
a concentration of 1 × 106/mL in 24-well plates in RPMI-1640 (l-glutamine and sodium bicarbonate)
(Sigma Aldrich, St. Louis, MO, USA) supplemented with 10% FCS, 50 µM 2-mercaptoethanol,
and 1% penicillin/streptomycin. Cells were incubated at 37◦C, 5% CO2. After resting of the cells for
24 h, the different compounds (either WIV (10 µg/mL corresponding to viral hemagglutinin (HA),
split (10 µg/mL corresponding to HA), influenza peptides (2.5 nmol/mL), or CEF pool (2 µg/mL)) were
added and remained with the cells for the rest of the culture period. On day 5, 50% of the medium
was replaced with fresh medium, and the cells were cultured for an additional 5 days. For cells to
be analyzed by flow cytometry, Brefeldin A (eBioscience, San Diego, CA, USA) was added 12 h prior
to harvesting.
2.5. Multiparameter Flow Cytometry
On day 10, Brefelding-treated cells were harvested and washed using FACS buffer (1X PBS
supplemented with 2% FCS and 1 mM EDTA), followed by staining with a fixable viability dye
(Viobility 405/450, Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 min at room temperature.
Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm Kit (BD Biosciences). Briefly,
cells were incubated in the Fixation/Permeabilization solution for 20 min at 4◦C, followed by the
addition of BD Perm/Wash Buffer (1X). Cells were then incubated with both solutions for an additional
15 min and then centrifuged at 350 g for 5 min (Allegra X-15R, SX 4750/SX4750A Beckman Coulter; Brea,
CA, USA). Intracellular staining with anti-IFNγ, or anti-IL21 and anti-IL12 (Miltenyi Biotech, Bergisch
Gladbach, Germany), was performed, followed by surface staining with antibodies to CD3, CD4, CD8,
CD25, CD107, CCR7, CD45RO, CXCR5, and ICOS (Appendix A Table A2) (all from Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s instructions. For the proliferation
assays, on day 0, cells were incubated with 2.5 µM carboxyfluorescein succinimidyl ester (CFSE) for
8 min, washed 3 times with CFSE buffer (PBS, 10% FBS), and seeded as mentioned above. Cells were
acquired using a FACSVerse (BD Bioscience, San Jose, CA, USA), and data were analyzed using
FlowLogic (Miltenyi Biotec, Bergisch Gladbach, Germany).
2.6. ELISpot
On day 9, MultiScreen HTS IP filter plates (MabTech, Stockholm, Sweden) were coated with
5 µg/mL of IFNγ mAB 1-DK (MabTech, Stockholm, Sweden) in PBS and incubated overnight at 4 ◦C.
After 24 h, plates were washed with 1X PBS and incubated with 100µL of X-VIVO 15 medium (Lonza) for
an hour at 37◦C with 5% CO2. Treated PBMCs were harvested, counted, and resuspended in an X-VIVO
15 medium to be seeded in triplicate at a concentration of 3 × 105/100 µL. After seeding, cells were
re-stimulated with either WIV or split vaccine (10 µg/mL HA), influenza peptides (1.25 nmol/mL),
or CEF (2 µg/mL pool) and incubated overnight at 37 ◦C, 5% CO2. Twenty-four hours after stimulation,
plates were thoroughly washed with PBS/Tween 0.05%, followed by incubation with mAb 7-B6-1-biotin
(1:3000, Mabtech, Stockholm, Sweden) for 2 h at room temperature in the dark. Plates where then
washed and incubated with extravidin-alkaline phosphatase (ALP) (1:1000) for 1 h at room temperature.
Finally, plates were washed and developed (substrate solution: BCIP/NBT ALP in miliQ water) for
7 min. The frequency of IFN-γ producing cells was measured using an AID ELISpot/Fluorospot reader
and analyzed with the AID ELISpot 6.0 iSpot software (Strassberg, Germany).
2.7. Statistical Analysis
Comparisons were performed using the Wilcoxon matched-pair T test, assuming a non-Gaussian
distribution and a 95% confidence level or using the Friedman test with post hoc Dunnett’s multiple
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comparison test. A p-value < 0.05 was considered significant and is indicated by *, ** stand for 0.01
and *** for 0.001. Statistical analyses were performed with GraphPad Prism version 7.0 (GraphPad
Software, San Diego, CA, USA).
3. Results
3.1. Antigen-Specific T Cells Expand Upon In Vitro Stimulation with WIV Vaccines
To establish a PBMC-based system to assess vaccine-induced T cell responses in vitro, we first set
out to understand the kinetics of the T cell responses over time. Hence, freshly thawed unfractionated
PBMCs were rested overnight and stimulated from day one onwards with the H5N1-derived WIV
influenza vaccine or mock-stimulated with PBS. At different time points, the cells were harvested for
intracellular staining of IFNγ followed by flow cytometric analysis (see Appendix A Figure A1 for
gating strategy). In WIV-treated PBMC cultures, influenza-specific T cells were detected from day two
onwards, although initially at low frequency, confirming the presence of influenza-specific T cells in
our donors. Overall, the percentages of IFNγ-producing T cells in WIV-treated cell cultures remained
low until day seven but thereafter increased ~2- to 6-fold until day 10 for both CD4+ and CD8+ T cells
(Figure 1A,B). No expansion was observed in PBS-treated cell cultures.
To get a better picture of the total amount of IFNγ produced per T cell subtype, we calculated
the integrated median fluorescence intensity (iMFI) as the product of cell frequency and median
fluorescence intensity (MFI). As previously stated, the iMFI depicts the total functional response of a
given cytokine [8]. Already by day two, we observed that CD8+ T cells produced higher amounts
of IFNγ in WIV-stimulated than in mock-treated PBMC cultures (Figure 1C). On subsequent days,
the amount of IFNγ generated (iMFI) increased in WIV-stimulated cultures and was significantly
higher than in PBS-treated PBMCs for both T cell populations from day seven onwards. On day 10,
the total amount of IFNγ in CD4+ and CD8+ T cells in WIV-treated PBMCs was significantly higher
than on days two and five (Figure 1C). In contrast, the total amount of IFNγ produced by PBS-treated
cells remained similar throughout the experiment.
To determine whether the observed increase in frequency of IFNγ-producing T cells in WIV-treated
PBMC cultures was due to proliferation, PBMCs were labeled with CFSE and exposed to WIV,
CEF pool (positive control for CD8 stimulation), or PBS for 10 days and analyzed by flow cytometry.
The proliferation of CD4 T cells was observed for all conditions but was stronger in the WIV- and
PBS-treated than in the CEF-treated cultures (Appendix A Figure A2A). However, only the WIV-treated
and not the PBS- or CEF-treated PBMCs showed the production of IFNγ and only in the proliferating
(CFSELOW) fraction (Appendix A Figure A2B). In the CD8+ subset, WIV induced stronger proliferation
than CEF and PBS. As in the CD4+ T cell subset, only cells stimulated with WIV (and CEF) produced
IFNγ and IFNγ production was restricted to the proliferating fraction (Appendix A Figure A2C).
These results corroborated that influenza-specific responses can be detected in PBMCs from healthy
individuals after two days of stimulation with WIV, as expected. The culture of unfractionated PBMCs
with WIV for a 10-day period enabled the expansion of, most probably, pre-existing, antigen-specific
CD4+ and CD8+ T cells. The total IFNγ response, defined as iMFI, increased by a factor of 100 in both T
cell populations. Given this observation, we decided to focus on day 10 for the following experiments.
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3.2. T Cell Responses in Long-Term PBMC Cultures Are Vaccine Formulation-Specific
We next determined whether the T cells in our in vitro system would respond differently to
different types of vaccines. For this purpose, we used two different influenza vaccine formulations;
WIV and split. These vaccines have the same protein content but differ in their stimulatory capacity,
as WIV contains RNA capable of signaling through Toll-like receptor 7 (TLR7) while split does
not [9]. WIV particles are also more easily taken up by APCs than split, which consists of solubilized
particles [10]. Furthermore, WIV retains membrane fusion properties, thus favoring CTL responses [11].
We first performed an ELISpot assay, which is considered to be more sensitive for the detection of
antigen-specific T cells than intracellular cytokine staining (ICS) [12] but does not allow to discriminate
between CD4- and CD8- derived cytokines. After ten days of culture, we observed that the PBMCs
responded equally well to both vaccines by displaying high numbers of IFNγ-producing cells. Only a
few background IFNγ-producing cells were observed after treatment with PBS (Figure 2A).
Having established the antigen-specific responses by ELISpot assay, we characterized the
responding T cells in more detail using ICS and multicolor flow cytometry. We observed that
treatment with both vaccines led to a significantly higher number (%) of IFNγ-producing CD4+ and
CD8+ T cells and to a higher total amount (iMFI) of IFNγ than treatment with PBS. The total amount
of IFNγ (iMFI) induced in the CD4+ and the CD8+ T cells by WIV stimulation was significantly
higher than that elicited by the split vaccine (Figure 2B). Next, we assessed the activation profile
of the cells by checking the expression of the interleukin (IL-) 2 receptor α-subunit (CD25), a late
activation marker [13]. We observed that exposure to both WIV and split vaccines resulted in higher
percentages of CD8+CD25+ T cells than observed in PBS-treated cultures, while it did not affect the
percentages of CD4+CD25+ T cells (Figure 2C). Additionally, we determined the cytotoxic potential
of T lymphocytes by staining for the lysosome-associated membrane protein LAMP-1 (CD107) [14].
Intriguingly, both vaccines elicited upregulation of this marker not only in CD8+ but also in CD4+
cells, demonstrated by significantly higher percentages of CD107+ cells than in PBS-treated cultures
(Figure 2D). Unexpectedly, the split vaccine induced significantly higher percentages of CD4+CD107+
than WIV.
Altogether, these observations highlight the suitability of the used in vitro PBMC-based platform
for a detailed characterization of antigen-specific responses to different influenza vaccine formulations.
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3.3. Memory T Cell Subsets Are the Main Source of Antigen-Specific Responses In Vitro
Classification of T cells into different memory subsets has been extensively used to understand the
functional potential of these cells, especially in the context of vaccination [15–17]. On the basis of the
expression of CCR7 and CD45RO, the following subsets are distinguished [18]: naïve (CD45RO-CCR7+),
central memory (TCM: CD45RO+CCR7+), effector memory (TEM: CD45RO+CCR7−), and terminally
differentiated (TEMRA: CD45RO-CCR7−) T cells (gating strategy depicted in Appendix A Figure A3A).
In order to better understand the T cell responses evoked by exposure to WIV and split, we checked
the induction of antigen-specific responses in each subset by flow cytometry.
Naïve T cells had only a minor contribution to the total IFNγ response, although the amount
of IFNγ produced by naïve CD4+ cells differed significantly between split and PBS-treated PBMCs
(Figure 3A). Stimulation with both vaccines led to significantly higher amounts of total IFNγ in
all three CD4+ memory subsets (TCM, TEM, TEMRA) and two of the CD8+ memory subsets (TCM,
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TEM) than observed in the PBS controls. Across all memory T cell subsets, there was a consistently
higher production of IFNγ in WIV-stimulated than in split-stimulated PBMCs; this difference was
significant for CD4 TEM, CD8 TEM, and CD8 TCM. (Figure 3A). To further discriminate and quantify
the contribution from each of the memory subsets to the antigen-specific responses, we performed a
back-gating analysis in which we phenotyped—based on CCR7 and CD45RO expression—the IFNγ+
population (gated as in Appendix A Figure A3B). This enabled us to determine to which T cell subset
the IFNγ+ cells allocated. In both the CD4+ and CD8+ T cell populations, the TEM subset contributed
most strongly to the production of IFNγ, followed by the TCM subset. The subset allocation of the
IFNγ-producing T cells was independent of the stimulus (WIV, split, or CEF) used.
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Figure 3. WIV and split vaccines induce the production of IFNγ by central memory and effector
memory T cells. (A) Vaccine-stimulated PBMCs were phenotyped into naïve, TCM, TEM, TEMRA by
staining for CCR7 and CD45RO, and the production of IFNγ in each subpopulation was assessed
by ICS (for gating strategy see Appendix A Figure A3A). Depicted are the iMFIs indicating the total
production of IFNγ induced by WIV (purple), split (blue), or PBS (grey) in each T cell subset for each
donor (n = 7). Hashes (#) indicate statistical significance compared to PBS-treated cultures, diamonds
() indicate the statistical difference between WIV and split vaccines, and asterisks (*) indicate the
statistical difference between the subsets. For the CD4 T cells, the log iMFI of TEMRA was below 10
and is therefore not visible. (B) Pie chart of a representative donor depicting the contribution of naïve,
TCM, TEM, and TEMRA to IFNγ production as determined by back-gating of the IFNγ+ population (by
assessing the expression of CCR7 and CD45RO of IFNγ+ cells, see Appendix A Figure A3B). Each pie
represents a single condition (WIV, split, or CEF) for one donor. p < 0.05 = *, ** <0.01 and *** <0.001.
p < 0.05 = #, ## <0.01 and ### <0.001.
Overall, these experiments led us to conclude that memory T cells, specifically CD4 TEM,
were primarily responsible for the antigen-specific responses seen upon in vitro stimulation with WIV
and split vaccines.
3.4. PBMCs Display Antigen-Specific Responses upon Stimulation with Influenza Peptides
In order to validate our approach to assess vaccines in vitro, we determined the induction of
antigen-specific responses by peptide influenza vaccine candidates. For this purpose, we selected,
from a previous study by Wilkinson et al. [7], two peptides representing CD4 epitopes and two peptides
representing CD8 epitopes. For the peptide selection, we looked for those epitopes conserved across
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different influenza strains and to which responses were most frequently found in the human population.
We first investigated whether these peptides could induce any IFNγ production. To this end, PBMCs
were stimulated either with CD4 peptides (CD4 Mix), CD8 peptides (CD8 Mix), or a combination of
the peptides (CD4/CD8 Mix). PBMCs stimulated with either of the peptide mixes or with CEF as a
positive control contained significantly higher percentages of IFNγ+ CD4 and CD8 T cells than found
in PBS-treated controls (Figure 4A). The CD4 peptide mix stimulated CD4+ but also CD8+ T cells,
and also, the CD8 peptide mix stimulated both cell populations. This was in line with the in silico
analysis of MHC binding (using SYFPEITHI), which predicted the promiscuity of the peptides that the
CD4 peptides could potentially bind to MHC-I molecules and the CD8 peptides to MHC-II molecules.
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Figure 4. Peptides derived from influenza virus proteins stimulate the production of IFNγ by central
memory and effector memory T cell subsets. PBMCs were stimulated with different combinations of
influenza peptides targeting CD4+ or CD8+ T cells or with a mix of both. (A) Ten days after culture,
cells were assessed for the expression of IFNγ, depicted are the percentages of the cells expressing IFNγ
or the iMFIs for CD4+ and C8+ T cells (n = 7). (B) Production of IFNγ by each T cell subset (naïve, TCM,
TEM, TEMRA) was assessed by determining the iMFI. Each symbol represents one donor. Significance
was assessed by comparing each condi ion to the PBS control (n = 5). p < 0.05 = *.
We additionally characterized the T cell subsets involved in the antigen-specific responses. Similar
to that found for WIV and split vaccines, either of the mixes induced minor responses of the naïve T cell
compartment and the TCM and TEM subsets were the main contributors to IFNγ production (Figure 4B).
In addition, we observed higher donor-to-donor variation in response to the peptides than to WIV
and split vaccines, as is to be expected due to the heterogeneity in HLA haplotypes in the population.
Taken together, the fact that the T cells readily responded to peptide vaccine candidates confirms the
versatility and robustness of our in vitro approach to assess antigen-specific T cell reactions.
3.5. Induction of Follicular T Helper Cells by Influenza Vaccines In Vitro
Recent studies aiming at unraveling the role of TFH cells in the context of vaccination have shown
that expansion of this subset in blood after vaccination can predict the titer of neutralizing antibodies
at later time points [19]. Given this, we set o t to assess whether we could detect the expansion and
activation of these cells in our in vitro approach. We identified TFH cells as CD4+CXCR5+ lymphocytes
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and assessed their activation status by measuring the expression of inducible T-cell co-stimulator
(ICOS) alone or in combination with IL-21 by flow cytometry [19–22].
After 10 days of in vitro culture, PBMC cultures stimulated with WIV or split vaccine contained
similar frequencies of TFH cells (CD4+CXCR5+) as found in mock-stimulated controls (Figure 5A).
However, in WIV-treated PBMCs, a significantly higher percentage of the TFH cells displayed an
activated phenotype (ICOS+CD4+CXCR5+) than in mock-stimulated PBMCs (Figure 5B). Accordingly,
the percentages of ICOS-CD4+CXCR5+ T cells were lower in WIV- than in PBS-treated cells. For the
split vaccine, an increase in activated (ICOS+) TFH was also observed, but this was not significant.
Further zooming in on the activated TFH population revealed that many of these cells were able to
produce IL-21 (Figure 5C). In contrast, non-activated (ICOS-) TFH cells were not able to produce this
cytokine (Appendix A Figure A4). Thus, activation was required for cytokine production and was
achieved by stimulation with WIV and, to a lower extent, by stimulation with the split vaccine.
 
 
at later time points [19]. Given this, we set out to assess whether we could detect the expansion and 
activation of these cells in our in vitro approach. We identified TFH cells as CD4+CXCR5+ lymphocytes 
and assessed their activation status by measuring the expression of inducible T-cell co-stimulator 
(ICOS) alone or in combination with IL-21 by flow cytometry [19–22].  
After 10 days of in vitro culture, PBMC cultures stimulated with WIV or split vaccine contained 
similar frequencies of TFH cells (CD4+CXCR5+) as found in mock-stimulated controls (Figure 5A). 
However, in WIV-treated PBMCs, a significantly higher percentage of the TFH cells displayed an 
activated phenotype (ICOS+CD4+CXCR5+) than in mock-stimulated PBMCs (Figure 5B). Accordingly, 
the percentages of ICOS-CD4+CXCR5+ T cells were lower in WIV- than in PBS-treated cells. For the 
split vaccine, an increase in activated (ICOS+) TFH was also observed, but this was not significant. 
Further zooming in on the activated TFH population revealed that many of these cells were able to 
produce IL-21 (Figure 5C). In contrast, non-activated (ICOS-) TFH cells were not able to produce this 
cytokine (Appendix Figure A4). Thus, activation was required for cytokine production and was 
achieved by stimulation with WIV and, to a lower extent, by stimulation with the split vaccine.  
 
Figure 5. WIV and split vaccines induce the activation and the production of IL-21 in TFH cells. Human 
PBMCs were stimulated with WIV (purple), split (blue), and PBS-treated (grey) for 10 days. Cells were 
harvested and analyzed with flow cytometry to assess the induction of TFH cells. (A) Dot plots show 
the percentage of TFH (CD4+CXCR5+) cells for each condition. (B) Representative flow cytometry plots 
depict the activated (ICOS+) and non-activated (ICOS−) TFH populations (CD4+CXCR5+) induced by 10-
day exposure to PBS, WIV, or split. The following dot plots show the percentages of activated and 
non-activated TFH in all the donors tested. (C) Flow cytometry plots representative of the induction of 
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Altogether, these results show that TFH cells can be readily identified in long-term cultures of 
unfractionated PBMCs and can be activated by stimulation with appropriate vaccines. Since activated 
TFH cells are the key to B cell stimulation [23–26], this result highlights the possibility of using long-
term PBMC cultures not only to assess T cell responses but also to predict vaccine immunogenicity 
in terms of antibody responses.  
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assess the effects of H5N1 influenza vaccines on human T cells. By using a multicolor flow cytometry 
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Figure 5. WIV and split vaccines induce the activation and the production of IL-21 in TFH cells. Human
PBMCs were stimulated with WIV (purple), split (blue), and PBS-treated (grey) for 10 days. Cells were
harvested and analyzed with flow cytometry to assess the induction of TFH cells. (A) Dot plots show
the percentage of TFH (CD4+CXCR5+) cells for each condition. (B) Representative flow cytometry plots
depict the activated (ICOS+) and non-activated (ICOS−) T populations (CD4+CXCR5+) induced by
10-day exposure to PBS, WIV, or split. The following dot plots show the percentages of activated and
non-activated TFH in all the donors tested. (C) Flow cytometry plots representative of the induction of
IL-21 upon treatment with the different vaccines. Dot plots depict the percentage of cells expressing
IL-21 and the iMFI of the respective population. p < 0.05 = * and ** <0.01.
Altogether, these results show that TFH cells can be readily identified in long-term cultures of
unfractionated PBMCs and can be activated by stimulation with appropriate vaccines. Since activated
TFH cells are the key to B cell stimulation [23–26], this result highlights the possibility of using long-term
PBMC cultures not only to assess T cell responses but also to predict vaccine immunogenicity in terms
of antibody responses.
4. Discussion
In this study, we examined whether long-term cultures of unfractionated PBMCs are suitable to
assess the effects of H5N1 influenza vaccines on human T cells. By using a multicolor flow cytometry
approach, we observed that: (1) stimulation of long-term cultures with WIV induced T cell expansion
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and the production of IFNγ; (2) T cells in long-term cultures responded to WIV, split, and peptide
vaccines in quantitatively distinct ways with responses to WIV being most pronounced; (3) responses
were derived mainly from memory subsets, TEM for both CD4+ and CD8+ T cells; (4) vaccines enhanced
the number of activated (ICOS+) TFH and activated TFH producing IL-21. These results demonstrate
the potential suitability of this long-term culture in vitro system for assessing the effects of vaccines
and vaccine candidates on human memory T cells.
Traditional culture systems for T cells either aim at determining antigen-specific memory responses
induced by a previous infection or vaccination or attempt to induce or expand antigen-specific T
cells in vitro [27–31]. For the determination of memory T cell responses, cells are harvested from
blood, stimulated for a short period of time with antigenic peptides or other stimuli, and responses
are assessed by techniques like proliferation assay, ELISpot assay, or intracellular cytokine staining.
Experimental systems for in vitro induction or expansion of antigen-specific T cells usually make use of
co-cultures of isolated DCs and autologous T cells [27–29,31,32]. However, this is a laborious approach
that involves isolation of monocytes and T cells from peripheral blood, differentiation of monocytes to
DCs, loading of DCs with antigen, and the combination of antigen-loaded DCs with T cells derived
from frozen PBMC fractions of the same donor [27]. The here proposed system of long-term PBMC
cultures for T cell evaluation is simple and robust and has the additional advantage that it enables the
crosstalk between different types of immune cells.
We observed that the strong expansion of antigen-specific T cells took place after an initial lag phase
of about seven days. The timing of this pronounced expansion is in line with other publications [33–36].
However, different from these studies, here we observed that expansion took place even in the absence
of exogenous cytokines (i.e., IL-2 or IL-21). This is in agreement with previous studies highlighting
the role of TCR signaling as a driving force for T cell proliferation [37]: TCR signaling leads to an
increase in intracellular Ca+2 concentrations, which in turn triggers IL-2 production [38,39]. Though
we have not formerly proven TCR engagement in the current study, it is tempting to speculate that the
strong T cell stimulation elicited by WIV resulted in exponentially increasing secretion of IL-2 over
time, which eventually allowed proliferation of the antigen-specific T cells [40]. Yet, the production of
endogenous IL-2 still needs to be verified. In our in vitro system, the addition of exogenous cytokines
thus appears unnecessary and might even reduce the discriminatory power of the system to distinguish
between vaccines with different immune cell-stimulating capacities. Nevertheless, it is worthwhile to
explore the advantages and disadvantages of cytokine addition in detail; cytokines might be necessary
when the system is going to be employed for de novo antigens. Different from standard cytotoxic T
lymphocyte (CTL) assays where T cell responses are measured five days after re-stimulation [41,42]
using a 10-day long-term culture approach allowed us to assess vaccine-induced responses in vitro
even though numbers of (pre-existing) antigen-specific cells were low initially.
Our results demonstrate that WIV and split vaccines induced antigen-specific T cell responses
of different magnitudes indicated by significantly higher amounts of total IFNγ produced in
WIV-stimulated than in split vaccine-stimulated PBMC cultures. Similar results were found by
Halbroth and colleagues who, using DC-T cell co-cultures, also observed an enhanced ability of WIV as
compared to the split vaccine to elicit virus-specific CD8+ T cell responses [30]. These results probably
reflect differences in the stimulatory properties of the two vaccines. Although both contain the same
proteins, they differ in their physical characteristics: WIV consists of intact virus particles, whereas the
split vaccine is composed mainly of protein aggregates or soluble proteins [8,11]. WIV particles are
easily taken up by APCs due to their structure and “optimal antigen organization” [10]. Furthermore,
WIV particles retain membrane fusion properties and can thus deliver influenza antigens directly
into the cytosol from where they have access to the MHC I presentation pathway for presentation to
CTLs [11]. Additionally, WIV is intrinsically adjuvanted with viral single-stranded RNA (ssRNA),
which, through the triggering of TLR7 and TLR8, leads to activation of DCs [9,43]. In contrast, the split
vaccine contains only minor amounts of ssRNA [43,44] (although there is some inconsistency about
this point in the literature [45]) and therefore has a reduced capacity to activate DCs [30]. Overall,
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the higher immunogenicity of WIV over split observed in this study is in line with previous reports
from in vivo studies. While an H5N1 WIV vaccine readily induced influenza-specific CD4+ T cells
in human volunteers [46], split vaccine at the same antigen dose (2 × 7.5 µg HA) did not unless
adjuvanted with AS03 [47]. In order to assess the sensitivity of our in vitro system, we additionally
tested candidate influenza peptide vaccines, which differ from WIV and split vaccines, by comprising
only two or four antigenic epitopes. In the long-term PBMC cultures, we could readily observe
antigen-specific responses to the peptides, although these were of lower magnitude than those induced
by WIV and split vaccines. These results underline the robustness of the developed in vitro system and
the possibility to use it to assess the relative capacity of vaccine candidates to elicit T cell responses.
Our results demonstrate that long term stimulation of PBMCs with WIV, split vaccine, or peptides
generally induced recall responses; thus, it activated memory rather than naïve T cells. Although the
vaccines we used were derived from the H5N1 virus (to which the blood donors were most likely naïve),
this was according to expectations since the dominant T cell epitopes of influenza are mainly located in
conserved areas of the internal viral proteins. CD4+ and CD8+ T cells responding to the vaccines mainly
had an effector memory phenotype, followed by cells with a central memory phenotype. In accordance
with our results, phase I clinical trials with split H5N1 vaccine or a vaccinia virus-based universal
influenza vaccine candidate have also shown a prevalence of effector memory over central memory
CD4+ T cell responses [48]. The predominance of effector CD4+ T cells was also observed when PBMCs
from naïve individuals were stimulated in vitro with live H1N1pdm09 virus [49]. The same study
reports that effector memory cells also prevailed among the influenza-specific CD8+ T cells, in line
with our results. Other authors investigating influenza-specific CD8+ T cell responses in vivo or in
human PBMCs also report on the predominance of CD8+ TEM rather than TCM [15,50–53].
Interestingly, we observed that exposure of long-term PBMC cultures to WIV or split vaccine,
though not changing the overall frequency of TFH cells, significantly enhanced the proportion of TFH
cells with an activated phenotype (ICOS+ and ICOS+IL21+). TFH cells are required for the generation
and maintenance of germinal center reactions in secondary lymphoid organs and the generation of high
affinity antibodies [19,20]. Recently, CD4+CXCR5+ T cells were identified as the circulating counterpart
of germinal center TFH cells [21]. Moreover, the number of activated blood TFH cells was found to
correlate with the magnitude of newly generated TFH cells in secondary organs [54], indicating that
the analysis of blood TFH subsets can help to get insight into ongoing TFH responses [55]. Studies in
influenza-vaccinated individuals revealed that the number of ICOS+ TFH cells in blood peaked at day
seven post-immunization and correlated with an increase of antibody titers and with the generation
of high-avidity antibodies [23,24]. Activated circulating TFH cells can thus serve as a biomarker
for vaccination success [26]. Conversely, activation of antigen-specific TFH cells in vaccine-exposed
long-term PBMC cultures as observed by us can likely be considered as an indication for the capacity
of a vaccine to stimulate TFH cells and thus antibody production in vivo. Yet, parallel in vitro and
in vivo studies are required to determine whether this is indeed the case.
CFSE dye dilution and/or intracellular staining for IFNγ have been used earlier to study T cell
responses ex vivo in cultures of human PBMCs [56–59]. Yet, these studies mainly report on successful
in vitro stimulation of T cells of recently vaccinated individuals. Other attempts to model the human
immune system in vitro, for example, the MIMIC® system, use approaches requiring separation
and sorting of cell populations and/or 3D reconstructions of lymphoid organs (reviewed in [60]).
These systems are highly sophisticated, yet, may be too cumbersome for many laboratories. In contrast,
our in vitro system consists of cultures generated from readily available PBMCs of healthy, not recently
vaccinated individuals. The system requires minimal manipulation of the cells, yet, proved suitable to
compare and characterize (recall) T cell responses to different types of vaccines in depth. Our approach
does not only allow the differentiation of responses between naïve T cells and different memory T cell
subtypes but also to dissect TFH responses.
A limitation of our study is that it demonstrates the suitability of the developed in vitro system
for the evaluation of T cell responses to previously encountered antigens but not to de novo antigens.
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Using influenza vaccines, we did observe only a minor response in the naïve T cell subset. Our study
thus proves the potential usefulness of the system for evaluation of (novel) vaccines intended for
boosting pre-existing immunity (e.g., against varicella, influenza, tetanus). Further experiments
should address the feasibility of assessing naïve T cell responses by making use of antigens to which
individuals are immunologically naïve. Preliminary experiments using Hepatitis B antigen imply
that the described in vitro system does also allow T cell activation with novel antigens (Tapia Calle,
unpublished observations). Yet, effective in vitro priming of naïve T cells will likely require further
fine-tuning and optimization of the system, for example, by using suitable cytokines. Another possible
limitation of our study and the described in vitro vaccine evaluation system is that it relies on the
use of human PBMCs, which has often been associated with the issue of donor variability and thus
inconsistencies in the results [61,62]. In our study, PBMCs of all donors responded in a similar way,
although not always to the same extent, underlining that the system can deliver meaningful information
despite donor variability. Furthermore, as mentioned above, an important issue will be to reveal
whether responses to vaccines, as observed in the long-term PBMC cultures, correlate with responses
the vaccines elicit in the donors in vivo. For such a direct validation, data from pre-vaccination PBMC
samples will need to be compared to data from post-vaccination PBMC samples as well as antibody
titers and T cell responses. Nevertheless, the correlation between the effectiveness of different vaccines
to activate T cells in our in vitro system and in in vivo trials (according to published data) is a strong
indication that the PBMC cultures deliver meaningful results.
5. Conclusions
The development of vaccines for clinical use is time-consuming and expensive since results
obtained in animal experiments are often poorly predictive for vaccine performance in humans.
Here we describe a model system consisting of long-term cultures of unfractionated human PBMCs
for assessing T cell recall responses to vaccines in detail. The system allows for the comparison
of the stimulatory capacity of different vaccine types, to identify responding T cell subpopulations
(naive, TCM, TEM, TEMRA) and to determine their cytokine production profile and cytotoxic potential.
In addition, the system is suitable for measuring vaccine effects on T follicular helper cells, which have
been described in vaccines as an early correlate of humoral immune responses. Given these properties,
the newly developed in vitro system can be used to gain insight into the effects and working mechanisms
of candidate vaccines in a human immune cell context, so far for vaccines, including recall antigens,
but in the future, hopefully also for de novo antigens. As such, the system is useful for the comparison
of candidate vaccines and can assist in the selection of the most promising candidates for further
clinical evaluation.
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Figure A2. WIV induces the expansion of IFNγ-producing CD4+ and CD8+ T cells. CFSE-treated PBMCs were incubated with WIV (purple), CEF (positive control,
yellow), or PBS (negative control, grey) for 10 days. (A) Representative proliferation histograms (left) and percentage of proliferating cells in the investigated donors
(right). (B) Representative histograms showing the gating of the IFNγ+ population in the proliferating fraction for WIV and PBS-treated PBMCs (left). Percentage of
IFNγ+ CD4+ and CD8+ T cells in the proliferating fraction (right) (n = 3). (C) Representative plots depicting the induction of IFNγ in the CFSELOW (proliferating) and
the CFSEHIGH (non-proliferating) population.
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Figure A3. Gating strategies for the discrimination of different T cell subsets and their production of IFNγ. (A) A seven-color flow cytometry panel was used to assess
the expression of CCR7, CD45RO, and IFNγ in human PBMCs. (B) Backgating analysis; starting from the IFNγ+ cells, cells were phenotyped based on their expression
of CD45RO and CCR7. (C) FMO controls for the discrimination of IFN+ responses. (D) CCR7 and CD45RO isotype controls to define the different T cell naïve and
memory subsets.
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Figure A4. (A) Non-activated TFH cells (ICOS-CD4+CXCR5+) do not produce IL-21. TFH that displayed
a non-activated phenotype (ICOS−) were also not able to produce IL-21. (B) Gating strategy for the
discrimination of TFH cells. A six-color flow cytometry panel was used to assess the expression of
CXCR5, ICOS and IL-21 in human PBMCs. (C) FMO controls were used to set the gating strategy to
define activated- and IL-21-producing TFH cells.
Table A1. Peptide’s details.
Epitope Protein Amino Acid Position CD4/CD8 Length
LKREITFHGAKEIALSY M 103–119 CD4 16
TYQRTRALVRTGMDPRM N 147–163 CD8 16
EALMEWLKTRPILSPLTK M 40–57 CD8 17
RMCNILKGKFQTAAQRAM NP 221–238 CD4 17
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Table A2. Overview of antibodies used for flow cytometry.
Panel 1. Activation, Cytotoxicity
and IFNγ of T Cells T Cells Panel 2. T Cell Subsets and IFNγ Panel 3. T Follicular Helper Cells
Live/Dead-Pacific Orange Live/Dead - Pacific Orange Live/Dead - Pacific Orange
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